[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342369-105":59,"doc-detail-342369-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","novel-wrn-helicase-inhibitors-selectively-target-microsatellite-unstable-cancer-cells-abstract","Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells - Abstract","","Microsatellite-unstable (MSI) cancers rely on the WRN helicase to resolve replication stress driven by expanded DNA (TA) n-dinucleotide repeats. WRN is a promising synthetic lethal vulnerability, and WRN helicase inhibitors are under development. The study uses CRISPR-Cas9 base editing to identify WRN residues essential in MSI cells, confirming the helicase domain as the principal drug target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/novel-wrn-helicase-inhibitors-selectively-target-microsatellite-unstable-cancer-cells-abstract/342369/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/novel-wrn-helicase-inhibitors-selectively-target-microsatellite-unstable-cancer-cells-abstract/342369.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are WRN helicase functions important in microsatellite-unstable (MSI) cancers?","Question",{"text":112,"@type":113},"MSI cancers require WRN helicase to resolve replication stress caused by expanded DNA (TA) n-dinucleotide repeats.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study identify WRN residues critical for targeting MSI cells?",{"text":117,"@type":113},"CRISPR-Cas9 base editing was used to map WRN residues important for MSI cell survival, validating the helicase domain as the primary drug target.",{"name":119,"@type":110,"acceptedAnswer":120},"What was shown about the therapeutic effect of the developed WRN inhibitors?",{"text":121,"@type":113},"Fragment-based screening enabled potent, selective covalent WRN helicase inhibitors that suppress MSI model growth in vitro and in vivo, consistent with mimicking WRN loss and inducing DNA double-strand breaks at expanded TA repeats.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342369,1790959453,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Europe PMC unders uthManuscripts Europe M eC und Author Manuscripts  \nEurope PMC Funders Group  \nAuthor Manuscript  \nCancer Discov. Author manuscript; available in PMC 2024 November 26.  \nPublished in final edited form as:  \nCancer Discov. 2024 August 2; 14(8): 1457–1475. doi:10.1158/2159-8290.CD-24-0052 .  \nNovel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells  \nGabriele Picco 1,* , Yanhua Rao2 , Angham Al Saedi 1 , Yang Lee2 , Sara F. Vieira 1 , Shriram Bhosle 1 , Kieron May6 , Carmen Herranz-Ors 1 , Samantha J. Walker1 , Raynold Shenje2 , Cansu Dincer1 , Freddy Gibson 1 , Ruby Banerjee 1 , Zoe Hewitson 1 , Thilo Werner4 , Joshua E. Cottom2 , Yang Peng2 , Nanhua Deng5 , Youyou Zhang2 , Eldridge Nartey2 , Leng Nickels2 , Philip Landis2 , Daniela Conticelli7 , Katrina McCarten 1 , Jacob Bush3 , Mamta Sharma 1 , Howard Lightfoot 1 , David House3 , Emma Milford3 , Emma K. Grant3 , Michal P Glogowski2 , Craig D. Wagner2 , Marcus Bantscheff4 , Anna Rutkowska-Klute4 , Cell Model Network UK Group, Francesca Zappacosta2 , Jonathan Pettinger3 , Syd Barthorpe 1 , H. Christian Eberl4 , Brian T. Jones8 , Jessica L. Schneck2 , Dennis J. Murphy2 , Emile E. Voest9 , Joshua P. Taygerly8 , Michael P. DeMartino2 , Matthew A. Coelho 1 , Jonathan Houseley6 , Geeta Sharma5 , Benjamin Schwartz2 , Mathew J. Garnett 1,*  \n1Wellcome Sanger Institute, Cambridge, UK  \n2GSK, Upper Providence, PA, US 19426  \n3GSK, Stevenage, UK, SG1 2NY  \n4GSK, 69117 Heidelberg, Germany  \n5GSK, Cambridge, MA, US 02139  \n6 Epigenetics Programme, Babraham Institute, Cambridge, UK  \n7Candiolo Cancer Institute, Italy  \n8 IDEAYA Biosciences, South San Francisco, CA 94080  \n9 Netherlands Cancer Institute, Amsterdam, the Netherlands  \nAbstract  \nThis work is licensed under a BY 4.0 International license.  \n*Corresponding authors: Gabriele Picco; [gabriele.picco@sanger.ac.uk](gabriele.picco@sanger.ac.uk), Mathew J. Garnett; [mathew.garnett@sanger.ac.uk](mathew.garnett@sanger.ac.uk), Address: Wellcome Sanger Institute. Cambridge, UK. CB10 1SA, Phone Number: +44 1223 494878.  \nDeclaration of Interests  \nAstraZeneca, GlaxoSmithKline, and Astex Pharmaceuticals have awarded MJG research grants. Additionally, MJG and EV are founders and advisors at Mosaic Therapeutics. GP serves in a consultant role for Mosaic Therapeutics. All authors listed with an affiliation to GSK are GlaxoSmithKline (GSK) employees except JEC and YP, who are no longer GSK employees. SV is currently employed at Astrazeneca.  \nAuthor contributions  \nGP, YR, BS, and MJG conceptualized the study, with additional conceptual and design efforts by JB, DH, FZ, MD, JPT, MB, and TW. Experiments were conducted by GP, AAS, SV, SW, RB, DC, EM, EKG, CW, JP, RS, BJ, MG, DM, YL, ND, JC, and YP. SB, ZW, FG, YL, and PL performed drug screening experiments. HL and ARK performed curve fitting. Data analysis was conducted by GP, SB, MC, with MC also providing key reagents and expertise for base editing experiments. The base editing sgRNA library was cloned by MS. The gRNA library design was a collaborative effort involving KM, MC, GP, GS, and MB. EV, EM, EKG, CW, and JP contributed by sharing key reagents. JH and KM performed and analyzed TrAEL-seq experiments. The manuscript was written by GP and MJG, with review and input from all contributing authors.  \nEurope PMC unders uthManuscripts Europe M eC und Author Manuscripts  \nPicco et al. Page 2  \nMicrosatellite-unstable (MSI) cancers require WRN helicase to resolve replication stress due to expanded DNA (TA) n-dinucleotide repeats. WRN is a promising synthetic lethal target for MSI tumours, and WRN inhibitors are in development. Here, we used CRISPR-Cas9 base editing to map WRN residues critical for MSI cells, validating the helicase domain as the primary  \ndrug target. Fragment-based screening led to the development of potent and highly selective WRN helicase covalent inhibitors. These compounds selectively suppressed MSI model growth In vitro and In","cbCaikp6kjDZvPxo","https://ap.wps.com/l/cbCaikp6kjDZvPxo","pdf",3202312,37,"English","# Abstract\n# Keywords\n# Introduction\n## MSI and mismatch repair\n## Immunotherapy and resistance\n## WRN helicase biology and rationale","[{\"question\":\"Why are WRN helicase functions important in microsatellite-unstable (MSI) cancers?\",\"answer\":\"MSI cancers require WRN helicase to resolve replication stress caused by expanded DNA (TA) n-dinucleotide repeats.\"},{\"question\":\"How did the study identify WRN residues critical for targeting MSI cells?\",\"answer\":\"CRISPR-Cas9 base editing was used to map WRN residues important for MSI cell survival, validating the helicase domain as the primary drug target.\"},{\"question\":\"What was shown about the therapeutic effect of the developed WRN inhibitors?\",\"answer\":\"Fragment-based screening enabled potent, selective covalent WRN helicase inhibitors that suppress MSI model growth in vitro and in vivo, consistent with mimicking WRN loss and inducing DNA double-strand breaks at expanded TA repeats.\"}]","Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells - Abstract | PDF",1790046287,93,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44cd8a1b96f0979ac600a6c3a748f9b1.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37f10ff0b23610e54418973299c0402e.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f711c53410155c51f67fca9492858d8a.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62d8ff09719d3304c223aac04fefb163.webp",980,1268]